Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ipilimumab + nivolumab + talimogene laherparepvec
- Development stage
- Preclinical
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intravenous, Intralesional
01
Overview
A triple combination immunotherapy regimen consisting of ipilimumab (CTLA-4 inhibitor), nivolumab (PD-1 inhibitor), and talimogene laherparepvec (T-VEC, an oncolytic virus). This combination leverages three different immunotherapeutic mechanisms to potentially enhance antitumor activity in advanced melanoma. T-VEC selectively replicates in and lyses tumor cells, releasing tumor-derived antigens and producing GM-CSF locally. Ipilimumab enhances T-cell recruitment and prevents exhaustion of activated T cells. Nivolumab further enhances antitumor immunity by blocking the PD-1/PD-L1 pathway.
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)
Beyond the preview
Go deeper on ipilimumab + nivolumab + talimogene laherparepvec.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ipilimumab + nivolumab + talimogene laherparepvec.